Hospital
Hca Health Services of Florida, INC.
Hca Health Services of Florida, INC. was paid $11.43M by Medicaid between Jan 2018 and Dec 2024, across 167 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF FLORIDA, INC.
PORT ST LUCIE, FL 34952
PORT ST LUCIE, FL 34952
33aNPI1538115696assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.43M
24GClaims488,865
24DCodes billed167
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#44 of 163
Median peer was paid$4.77M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,848 | $362K | |
| 2019 | 82,125 | $1.11M | |
| 2020 | 67,057 | $889K | |
| 2021 | 93,639 | $2.30M | |
| 2022 | 114,148 | $3.27M | |
| 2023 | 65,753 | $2.22M | |
| 2024incomplete | 35,295 | $1.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 44,717 | 40,846 | $3.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 28,303 | 24,168 | $1.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.0% | 8,784 | 8,171 | $691K |
| 80053 | Comprehensive metabolic panel | 4.8% | 21,580 | 17,977 | $546K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.7% | 2,729 | 2,413 | $427K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 2,855 | 2,541 | $426K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 4,871 | 4,017 | $416K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.9% | 5,868 | 4,536 | $330K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 4,057 | 1,339 | $298K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 2,887 | 2,652 | $277K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 8,733 | 6,524 | $224K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 1,203 | 1,053 | $193K |
155 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 3,123 | $122K |
| 87070 | 1.1% | 10,012 | $121K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 4,276 | $118K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,848 | $109K |
| 87275 | <1% | 10,324 | $104K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,462 | $102K |
| G0378 | Hospital observation service, per hour | <1% | 5,755 | $81K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,352 | $71K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,778 | $69K |
| 81001 | <1% | 12,786 | $53K | |
| 81003 | <1% | 7,653 | $50K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 206 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,877 | $44K |
| A9270 | Non-covered item or service | <1% | 10,774 | $42K |
| 76830 | Ultrasound, transvaginal | <1% | 593 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,576 | $41K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 877 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12,654 | $28K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 639 | $27K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,200 | $27K |
| 85027 | <1% | 32,186 | $24K | |
| 81025 | <1% | 5,210 | $24K | |
| 84702 | <1% | 2,280 | $23K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 323 | $22K |
| J3490 | Unclassified drugs | <1% | 846 | $22K |
| 73610 | <1% | 1,064 | $21K | |
| 73630 | <1% | 1,265 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,571 | $20K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 461 | $19K |
| 93971 | <1% | 350 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 465 | $18K |
| 12001 | <1% | 216 | $17K | |
| 73130 | <1% | 926 | $17K | |
| 73564 | <1% | 1,070 | $16K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,128 | $16K |
| 87077 | <1% | 2,322 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,536 | $14K |
| 87088 | <1% | 3,133 | $12K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,116 | $12K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,205 | $12K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 281 | $11K |
| 12011 | <1% | 148 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,401 | $11K |
| 84484 | <1% | 9,595 | $11K | |
| 76801 | <1% | 1,592 | $10K | |
| 73030 | <1% | 765 | $10K | |
| 73110 | <1% | 582 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 635 | $9K |
| 10060 | <1% | 61 | $8K | |
| 72131 | <1% | 166 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,580 | $8K |
| 97163 | <1% | 380 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,766 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,336 | $7K |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | <1% | 168 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 294 | $6K |
| S0028 | Injection, famotidine, 20 mg | <1% | 764 | $6K |
| 84703 | <1% | 5,529 | $6K | |
| 87040 | <1% | 2,481 | $6K | |
| 74018 | <1% | 434 | $6K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 85 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,325 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 571 | $5K |
| 80047 | <1% | 133 | $5K | |
| 86850 | <1% | 244 | $5K | |
| 87807 | <1% | 3,167 | $5K | |
| 87400 | <1% | 10,144 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,061 | $4K |
| 84112 | <1% | 50 | $4K | |
| 87205 | <1% | 1,984 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,752 | $3K |
| 85610 | <1% | 3,141 | $3K | |
| 73080 | <1% | 212 | $2K | |
| 85730 | <1% | 2,672 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 74 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,475 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,064 | $2K |
| 87430 | <1% | 6,650 | $2K | |
| 72100 | <1% | 57 | $2K | |
| 83735 | <1% | 2,963 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,749 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,865 | $1K |
| 82553 | <1% | 391 | $1K | |
| 87276 | <1% | 10,320 | $1K | |
| 80076 | <1% | 896 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,274 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,998 | $1K |
| 82550 | <1% | 1,109 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 748 | $1K |
| 83690 | <1% | 8,766 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 566 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 95 | $1K |
| 73502 | <1% | 190 | $952.34 | |
| 85379 | <1% | 1,816 | $936.33 | |
| 73590 | <1% | 134 | $923.20 | |
| 80061 | Lipid panel | <1% | 997 | $845.74 |
| 83605 | <1% | 2,087 | $785.69 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,229 | $754.08 |
| 96376 | <1% | 1,143 | $598.86 | |
| 86140 | <1% | 671 | $594.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,518 | $591.60 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,909 | $584.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,046 | $531.48 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 504 | $480.53 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,057 | $470.69 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,527 | $454.62 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 316 | $388.47 |
| 85652 | <1% | 144 | $353.28 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,579 | $342.12 |
| 90715 | <1% | 244 | $321.35 | |
| 73090 | <1% | 109 | $308.47 | |
| 87186 | <1% | 123 | $307.55 | |
| 87420 | <1% | 1,032 | $227.48 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 260 | $221.36 |
| J2704 | Injection, propofol, 10 mg | <1% | 13 | $219.52 |
| 83880 | <1% | 998 | $196.02 | |
| 97597 | <1% | 100 | $182.49 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15 | $180.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,052 | $166.09 |
| 86900 | <1% | 1,340 | $125.69 | |
| 86901 | <1% | 1,338 | $125.69 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 353 | $110.24 |
| 84155 | <1% | 13 | $25.20 | |
| 84450 | <1% | 13 | $25.20 | |
| 84460 | <1% | 13 | $25.20 | |
| 82247 | <1% | 13 | $25.20 | |
| 84075 | <1% | 13 | $25.20 | |
| 82040 | <1% | 13 | $25.20 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 648 | $6.47 |
| 36415 | Collection of venous blood by venipuncture | <1% | 107 | $0.52 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 412 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 1,308 | $0.00 |
| 82248 | 0% | 116 | $0.00 | |
| 84156 | 0% | 14 | $0.00 | |
| 84100 | 0% | 33 | $0.00 | |
| 80143 | 0% | 30 | $0.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 54 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 21 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 195 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 232 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 172 | $0.00 |
| 80320 | 0% | 65 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 230 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 381 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 91 | $0.00 |
| 80329 | 0% | 26 | $0.00 | |
| 87184 | 0% | 28 | $0.00 | |
| 82077 | 0% | 64 | $0.00 | |
| 97750 | 0% | 17 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
| 94644 | 0% | 40 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 15 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARLINGHOUSE, NICOLE (CFO)